Factors affecting autologous peripheral blood hematopoietic stem cell collections by large-volume leukapheresis: a single center experience

Objective: To evaluate factors affecting peripheral bloodhematopoietic stem cell yield in patients undergoing large-volumeleukapheresis for autologous peripheral blood stem cell collection.Methods: Data from 304 consecutive autologous peripheral bloodstem cell donors mobilized with hematopoietic growth factor (usually G-CSF), associated or not with chemotherapy, at Hospital Israelita Albert Einstein between February 1999 and June 2010 were retrospectively analyzed. The objective was to obtain at least 2 x 106CD34+ cells/kg of body weight. Pre-mobilization factors analyzedincluded patient’s age, gender and diagnosis. Post mobilizationparameters evaluated were pre-apheresis peripheral white bloodcell count, immature circulating cell count, mononuclear cell count,peripheral blood CD34+ cell count, platelet count, and hemoglobinlevel. The effect of pre and post-mobilization factors on hematopoietic stem cell collection yield was investigated using logistic regression analysis (univariate and multivariate approaches). Results: Premobilization factors correlating to poor CD34+ cell yield in univariate analysis were acute myeloid leukemia (p = 0.017) and other hematological diseases (p = 0.023). Significant post-mobilization factors included peripheral blood immature circulating cells (p = 0.001), granulocytes (p = 0.002), hemoglobin level (p = 0.016), and CD34+ cell concentration (p < 0.001) in the first harvesting day. However, according to multivariate analysis, peripheral blood CD34+ cell content (p < 0.001) was the only independent factor that significantly correlated to poor hematopoietic stem cell yield. Conclusion: In this study, peripheral blood CD34+ cell concentration was the only factor significantly correlated to yield in patients submitted to for autologous collection

Isolation and characterization of mesenchymal stem cells obtained from reusable and disposable bone marrow collection filters

Objective: To compare human mesenchymal stem cells obtainedfrom reusable and disposable filters and to characterize themaccording to the criteria of the International Society of CellularTherapy. Methods: Human mesenchymal stem cells were isolatedfrom bone marrow collection reusable sets and compared with thoseobtained from disposable sets by washing the filters with cell culturemedia. The isolated cells were characterized according to the criteriaof the International Society of Cellular Therapy using flow cytometry,differentiation in vitro, and cytochemistry techniques. Results:Samples were obtained from disposable (n=3) and from reusablecollection sets (n=3). All samples obtained from bone marrowdisposable sets successfully produced mesenchymal stem cells. Allbone marrow derived mesenchymal stem cells were characterizedand fulfilled the criteria established by International Society of Cellular Therapy. Conclusion: This study showed that mesenchymal stemcells can also be obtained from reusable collection sets (which arestill used in several centers around the world) to be employed inresearch as an alternative and ethical source

Guidelines on cell therapy

The Brazilian Society for Blood and Marrow Transplantation (SBTMO) presents the Brazilian Guidelines on Hematopoietic Stem Cell Transplantatio

Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study

Associations between aplastic anemia and numerous drugs, pesticides and chemicals have been reported. This study conducted in Latin American countries shows a low incidence of aplastic anemia in this region of the world. Frequent exposure to benzene-based products increases this risk, while any association with specific drugs is uncertain

Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease

Background: Steroid-refractory acute graft-vs.-host disease (SR-aGVHD) is a complication of allogeneic hematopoietic stem cell transplantation with a dismal prognosis and for which there is no consensus-based second-line therapy. Ruxolitinib is not easily accessible in many countries. A possible therapy is the administration of mesenchymal stromal cells (MSCs). Methods: In this retrospective study, 52 patients with severe SR-aGVHD were treated with MSCs from umbilical cord (UC-MSCs) in nine institutions. Results: The median (range) age was 12.5 (0.3–65) years and the mean ± SD dose (×106/kg) was 4.73 ± 1.3 per infusion (median of four infusions). Overall (OR) and complete response (CR) rates on day 28 were 63.5% and 36.6%, respectively. Children (n = 35) had better OR (71.5% vs. 47.1%, p = 0.12), CR (48.6% vs. 11.8%, p = 0.03), overall survival (p = 0.0006), and relapse-free survival (p = 0.0014) than adults (n = 17). Acute adverse events (all of them mild or moderate) were detected in 32.7% of patients, with no significant difference in children and adult groups (p = 1.0). Conclusions: UC-MSCs are a feasible alternative therapy for SR-aGVHD, especially in children. The safety profile is favorable